SEHK:6990Biotechs
A Look at Kelun-Biotech (SEHK:6990) Valuation Following Breakthrough ADC Trial Results and New China Approvals
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is catching plenty of attention after unveiling positive late-stage trial results for its lead ADC therapies at the 2025 ESMO Congress. With both trastuzumab botidotin and sacituzumab tirumotecan outperforming standard treatments in breast and lung cancer, as well as new regulatory approvals in China, investors are taking a fresh look at the company’s commercial prospects.
See our latest analysis for Sichuan Kelun-Biotech...